Structure-activity relationship studies of CNS agents. XII. 1-[4-(4-aryl-1-piperazinyl)butyl]-3,4-dihydro-2(1H)-quinolinones: new 5-HT1A, 5-HT2 and D2 ligands with a potential antipsychotic activity. 1994

J L Mokrosz, and E Chojnacka-Wójcik, and A Dereń-Wesołek, and A Kłodzińska, and M Maćkowiak, and Z Bielecka, and M H Paluchowska
Department of Medicinal Chemistry, Polish Academy of Sciences, Kraków.

The synthesis of three 1-[4-(4-aryl-1-piperazinyl)butyl]-3,4-dihydro-2(1H)-quinolinones (5-7) was described and the receptor binding profile (5-HT1A, 5-HT2, alpha 1, D1, D2) was determined. It was found that m-chloro (5) and o-methoxy (6) derivatives are potent antagonists of the 5-HT1A, 5-HT2 and D2 receptors. It was shown that compound 6 resembles very well some atypical antipsychotics and may be considered as a novel agent of this class of drugs.

UI MeSH Term Description Entries
D008297 Male Males
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D012110 Reserpine An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. Raunervil,Raupasil,Rausedil,Rausedyl,Serpasil,Serpivite,V-Serp,V Serp
D003913 Dextroamphetamine The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic. d-Amphetamine,Curban,Dexamfetamine,Dexamphetamine,Dexedrine,Dextro-Amphetamine Sulfate,DextroStat,Dextroamphetamine Sulfate,Oxydess,d-Amphetamine Sulfate,dextro-Amphetamine,Dextro Amphetamine Sulfate,Sulfate, Dextroamphetamine,d Amphetamine,d Amphetamine Sulfate,dextro Amphetamine
D000697 Central Nervous System Stimulants A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. Analeptic,Analeptic Agent,Analeptic Drug,Analeptics,CNS Stimulant,CNS Stimulants,Central Nervous System Stimulant,Central Stimulant,Analeptic Agents,Analeptic Drugs,Central Stimulants,Agent, Analeptic,Agents, Analeptic,Drug, Analeptic,Drugs, Analeptic,Stimulant, CNS,Stimulant, Central,Stimulants, CNS,Stimulants, Central
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors
D012702 Serotonin Antagonists Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. 5-HT Antagonist,5-HT Antagonists,5-Hydroxytryptamine Antagonist,5-Hydroxytryptamine Antagonists,Antiserotonergic Agent,Antiserotonergic Agents,Serotonin Antagonist,Serotonin Blockader,Serotonin Blockaders,Serotonin Receptor Antagonist,Serotonin Receptor Blocker,Antagonists, 5-HT,Antagonists, 5-Hydroxytryptamine,Antagonists, Serotonin,Serotonin Receptor Antagonists,Serotonin Receptor Blockers,5 HT Antagonist,5 HT Antagonists,5 Hydroxytryptamine Antagonist,5 Hydroxytryptamine Antagonists,Agent, Antiserotonergic,Agents, Antiserotonergic,Antagonist, 5-HT,Antagonist, 5-Hydroxytryptamine,Antagonist, Serotonin,Antagonist, Serotonin Receptor,Antagonists, 5 HT,Antagonists, 5 Hydroxytryptamine,Antagonists, Serotonin Receptor,Blockader, Serotonin,Blockaders, Serotonin,Blocker, Serotonin Receptor,Blockers, Serotonin Receptor,Receptor Antagonist, Serotonin,Receptor Antagonists, Serotonin,Receptor Blocker, Serotonin,Receptor Blockers, Serotonin
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D014363 Tryptamines Decarboxylated monoamine derivatives of TRYPTOPHAN. Indolylethylamines,Triptan,Triptans

Related Publications

J L Mokrosz, and E Chojnacka-Wójcik, and A Dereń-Wesołek, and A Kłodzińska, and M Maćkowiak, and Z Bielecka, and M H Paluchowska
August 1994, Archiv der Pharmazie,
J L Mokrosz, and E Chojnacka-Wójcik, and A Dereń-Wesołek, and A Kłodzińska, and M Maćkowiak, and Z Bielecka, and M H Paluchowska
May 1994, Die Pharmazie,
J L Mokrosz, and E Chojnacka-Wójcik, and A Dereń-Wesołek, and A Kłodzińska, and M Maćkowiak, and Z Bielecka, and M H Paluchowska
December 2010, Bioorganic & medicinal chemistry letters,
J L Mokrosz, and E Chojnacka-Wójcik, and A Dereń-Wesołek, and A Kłodzińska, and M Maćkowiak, and Z Bielecka, and M H Paluchowska
January 1992, Polish journal of pharmacology and pharmacy,
J L Mokrosz, and E Chojnacka-Wójcik, and A Dereń-Wesołek, and A Kłodzińska, and M Maćkowiak, and Z Bielecka, and M H Paluchowska
June 1994, Journal of medicinal chemistry,
J L Mokrosz, and E Chojnacka-Wójcik, and A Dereń-Wesołek, and A Kłodzińska, and M Maćkowiak, and Z Bielecka, and M H Paluchowska
March 1995, Die Pharmazie,
J L Mokrosz, and E Chojnacka-Wójcik, and A Dereń-Wesołek, and A Kłodzińska, and M Maćkowiak, and Z Bielecka, and M H Paluchowska
July 1995, The Journal of pharmacology and experimental therapeutics,
J L Mokrosz, and E Chojnacka-Wójcik, and A Dereń-Wesołek, and A Kłodzińska, and M Maćkowiak, and Z Bielecka, and M H Paluchowska
June 1984, Chemical & pharmaceutical bulletin,
J L Mokrosz, and E Chojnacka-Wójcik, and A Dereń-Wesołek, and A Kłodzińska, and M Maćkowiak, and Z Bielecka, and M H Paluchowska
February 1998, Journal of medicinal chemistry,
J L Mokrosz, and E Chojnacka-Wójcik, and A Dereń-Wesołek, and A Kłodzińska, and M Maćkowiak, and Z Bielecka, and M H Paluchowska
April 1996, Chemical & pharmaceutical bulletin,
Copied contents to your clipboard!